$SUPN News

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?

Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest

Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

3 Reasons to Avoid SUPN and 1 Stock to Buy Instead

Supernus Pharmaceuticals to Participate in June Investor Conferences

Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate

5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Does Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)?

Supernus Pharmaceuticals Q1 Earnings Call Highlights

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q1 Estimates as Growth Products Drive 39% Revenue Surge

Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript

Supernus Pharmaceuticals Affirms FY2026 Sales Guidance of $840.000M-$870.000M vs $862.242M Est

Supernus Pharmaceuticals Q1 EPS $(0.04) Misses $(0.01) Estimate, Sales $207.705M Beat $192.918M Estimate

Supernus Pharmaceuticals Enters Asset Purchase Agreement With Navitor On April 1, 2026; To Buy Assets Related To NV-5138 Or SPN-820, Including IP And Inventory; Purchase Price Includes Phase 2b Study And Milestone Payments Up To $350M; Agreement Includes Five-year Non-Compete And Non-Solicitation Covenant